StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) stock

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.60−0.05 (-1.37%)

Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –

Anbio Biotechnology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was $5.77M, up 189.1% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.77M+189.1%
FY2024Dec 31, 2024$2.00M+1.8%
FY2023Dec 31, 2023$1.96M-80.8%
FY2022Dec 31, 2022$10.20M–

More Anbio Biotechnology figures

See a number that looks wrong?